Trends in post–heart transplant biopsies for graft rejection versus nonrejection. Issue 3 (4th May 2021)

• Record Type: Journal Article
• Authors: Jamil, Aayla K.; Afzal, Aasim; Nisar, Tariq; Kluger, Aaron Y.; Felius, Joost; Wencker, Detlef; Hall, Shelley A.; Kale, Parag
• Is Part Of: Proceedings. Volume 34:Issue 3(2021)
• Page Start: 345
• Page End: 348
• Publication Date: 2021-05-04
• Subjects: Endomyocardial biopsy -- national inpatient sample -- rejection; Medicine -- Periodicals; Medicine; Medicine -- Periodicals; Periodicals; Electronic journals; 616.005
• DOI: 10.1080/08998280.2021.1873032
• Languages: English
• ISSNs: 0899-8280

Abstract

Abstract: With alternatives such as gene profiling available for surveillance after orthotopic heart transplantation, we sought to evaluate the utilization of endomyocardial biopsies (EMBs) for hospitalized patients after heart transplantation. Surveillance EMBs in patients with and without complications were evaluated from the 2004 to 2014 National Inpatient Sample. Over the study period, there was no significant change in the number of EMB procedures performed ( P = 0.44). Of 37, 955 EMBs, 2283 (6%) were in the setting of graft complications, while 35, 672 EMBs were not related to graft complications. EMBs in graft complications did not show a significant increase in length of stay over time ( P = 0.06), but had a significant increase in cost over time ( P = 0.001). However, those with graft complications had an average of a 5-day longer length of stay ( P < 0.001) and costs that were $88, 816 ( P < 0.001) more expensive compared with those without graft complications. In conclusion, the vast majority of in-hospital EMBs were not related to heart transplantation complications. Nevertheless, EMB hospitalizations with graft complications showed significantly greater length of stay and cost. With the COVID-19 pandemic, it seems more effective to use minimal-contact health surveillance methods rather than invasive EMBs.